Can-Fite BioPharma Ltd.
CANF · AMEX
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.14 | 0.00 | 0.08 |
| FCF Yield | -19.89% | -14.11% | -13.10% | -10.62% |
| EV / EBITDA | -2.29 | -4.30 | -4.48 | -6.07 |
| Quality | ||||
| ROIC | -43.29% | -43.29% | -28.13% | -28.34% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.97 | 0.97 | 0.92 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.95% | -8.33% | -5.94% | -7.34% |
| Free Cash Flow Growth | 0.00% | -31.95% | 0.00% | 10.84% |
| Safety | ||||
| Net Debt / EBITDA | 2.61 | 2.61 | 2.34 | 2.34 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 38.71 | 0.00 |